Literature DB >> 9765617

Mutation analysis of the WT1 gene in myelodysplastic syndromes.

N Hosoya1, K Miyagawa, K Mitani, Y Yazaki, H Hirai.   

Abstract

The WT1 tumor suppressor gene was examined for mutations in a panel of 44 patients with myelodysplastic syndromes (MDS) including acute myelogenous leukemias (AML) secondary to MDS, using polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) analysis and sequencing analysis. A WT1 mutation was detected in one out of 17 cases of AML secondary to MDS. This mutation exists upstream of the zinc finger region and is predicted to produce a truncated WT1 protein lacking the zinc finger region. No mutations were detected in 27 MDS patients who had not progressed to AML. This is the first report of analysis for WT1 mutations in a large number of MDS patients, suggesting that WT1 mutations are uncommon in MDS. Abnormalities in this gene may, however, contribute to a small proportion of cases showing progression from MDS into AML.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765617      PMCID: PMC5921914          DOI: 10.1111/j.1349-7006.1998.tb00634.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  19 in total

1.  A single base pair polymorphism in the WT1 gene detected by single-strand conformation polymorphism analysis.

Authors:  N Groves; P N Baird; A Hogg; J K Cowell
Journal:  Hum Genet       Date:  1992-12       Impact factor: 4.132

2.  The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro.

Authors:  U Maurer; J Brieger; E Weidmann; P S Mitrou; D Hoelzer; L Bergmann
Journal:  Exp Hematol       Date:  1997-08       Impact factor: 3.084

3.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

Authors:  K M Call; T Glaser; C Y Ito; A J Buckler; J Pelletier; D A Haber; E A Rose; A Kral; H Yeger; W H Lewis
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

Review 4.  A clinical overview of WT1 gene mutations.

Authors:  M Little; C Wells
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

5.  Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance.

Authors:  L King-Underwood; K Pritchard-Jones
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

Review 6.  The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.

Authors:  F J Rauscher
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

7.  High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.

Authors:  L Bergmann; C Miething; U Maurer; J Brieger; T Karakas; E Weidmann; D Hoelzer
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

8.  The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.

Authors:  S Maheswaran; C Englert; P Bennett; G Heinrich; D A Haber
Journal:  Genes Dev       Date:  1995-09-01       Impact factor: 11.361

9.  Expression of the Wilms' tumor gene (WT1) in human leukemias.

Authors:  H Miwa; M Beran; G F Saunders
Journal:  Leukemia       Date:  1992-05       Impact factor: 11.528

10.  Mutations in the Wilms' tumor gene WT1 in leukemias.

Authors:  L King-Underwood; J Renshaw; K Pritchard-Jones
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

View more
  3 in total

Review 1.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

2.  Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Authors:  Peter Paschka; Guido Marcucci; Amy S Ruppert; Susan P Whitman; Krzysztof Mrózek; Kati Maharry; Christian Langer; Claudia D Baldus; Weiqiang Zhao; Bayard L Powell; Maria R Baer; Andrew J Carroll; Michael A Caligiuri; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

3.  Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.

Authors:  Golnaz Ensieh Kazemi-Sefat; Mohammad Keramatipour; Mohammad Vaezi; Seyed Mohsen Razavi; Kaveh Kavousi; Amin Talebi; Shahrbanoo Rostami; Marjan Yaghmaei; Bahram Chahardouli; Saeed Talebi; Kazem Mousavizadeh
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.